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Abstract  
AIM: Determine the levels of expression of pluripotency genes OCT-4 and SOX-2 before and after 
osteogenic differentiation of human mesenchymal stem cells (hMSCs). 
METHODS: Human MSCs were derived from the bone marrow and differentiated into osteoblasts. 
The analyses were performed on days 0 and 14 of the cell culture. In vitro differentiation was 
evaluated due to bone markers – alkaline phosphatase (AP) activity and the messenger RNA 
(mRNA) expression of AP and bone sialoprotein (BSP). The OCT-4 and SOX-2 expression was 
evaluated at mRNA level by real-time qPCR and at protein level by immunocytochemistry. 
RESULTS: In vitro cultures on day 14 showed an increase in AP activity and upregulation of AP 
and BSP gene expression. OCT-4 and SOX-2 in undifferentiated hMSCs on day 0 is detectable and 
very low compared to tumor cell lines as a positive control. Immunocytochemistry detected OCT-4 
in the cell nuclei prior (day 0) and post differentiation (day 14). On the same time points, cultures 
were negative for SOX-2 protein. 
CONCLUSION: Messenger RNA for pluripotency markers OCT-4 and SOX-2 isolated from hMSCs 
was less present, while OCT-4 protein was detected in cell nuclei prior and post differentiation into 
osteoblast lineage.  
 
 
 
 
Introduction 
 
Molecular mechanisms regulating proliferation 
and multipotency of MSCs have not been well 
understood. In contrast, the molecular basis of 
proliferation and multipotency of embryonic stem cells 
(ESCs) is in the focus of research for a long time and 
it is described in detail. Expression of the three 
transcription factors, OCT-4, SOX-2 and NANOG, is 
essential for the major properties of stem cells, self-
renewal and pluripotency [1, 2]. 
OCT-4 belongs to the family of Pou-domain 
transcriptional factors, and it is found in developing 
embryos, developing endoderm as well as developing 
neurectoderm [3–5]. OCT-4 together with SOX-2 up-
regulates the expression of NANOG [6]. OCT-4 is a 
dose-depended pluripotency regulator that controls 
lineage commitment of ESCs [7]. OCT-4 gene is 
expressed in tumor cells as well, but has not been 
found in differentiated tissues [8–10]. 
OCT-4 expression has been confirmed in 
bone marrow (protein and mRNA level) [11], dental 
pulp [12], heart, liver [13] and adipose tissue-derived 
stem cells [14]. 
SOX-2 is a member of the SRY-related HMG-
box (SOX) transcription factor family with a diverse 
role in stem cell potency and maintenance, embryonic 
development and cancer [15–18]. It is closely co-
regulated alongside core pluripotency factors OCT-4 
and NANOG in ESCs, embryonic carcinoma cells 
(ECCs) and induced pluripotent stem cells (iPSCs) 
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[18–20]. Recently, SOX-2 has been implicated in the 
maintenance and differentiation of adult stem cells. 
SOX-2 expression has been reported in bone marrow, 
neuronal tissues and sensory epithelia [11, 21]. 
It has been speculated that the same set of 
transcription factors plays an important role in the 
maintenance of multipotency and self-renewal of adult 
stem cells. Adult stem cells are present within the 
tissues with the purpose to repopulate them after 
injury or physiological loss. Human MSCs derived 
from bone marrow are progenitors that can 
differentiate into cells of multilineage, including 
osteogenic, chondrogenic, adipogenic and myogenic 
lineages [22–24]. Human MSCs, like human ESCs, 
are depended on fibroblast growth factor (FGF) to 
maintain self-renewal and pluripotency [25]. FGF 
inhibits differentiation by bone morphogenetic protein 
(BMP) signaling inhibition and sustain expression of 
OCT-4, SOX-2 and NANOG pluripotency associated 
genes [26]. Upon differentiation expression of 
pluripotency transcriptional factors should be 
downregulated [27]. However, there is a controversy 
among different research groups regarding the 
expression of pluripotency regulators in adult tissues 
[28]. Human MSCs exhibit heterogeneous 
characteristics with regard to morphology, proliferation 
rate and secreted factors as a consequence of 
variable gene expression pattern. Difference in gene 
expression is dependent of their intrinsic 
heterogeneity and culture conditions [29]. In particular, 
ex vivo expansion of hMSCs is used for cell therapy 
and tissue engineering. Therefore it is an important to 
characterize cells cultured in vitro for the expression 
of genes responsible for self-renewal ability in order to 
predict better their behavior. 
In this study, we evaluated the expression of 
OCT-4 and SOX-2, in cultured bone marrow-derived 
mesenchymal stem cells of human origin. There are 
no universal stem cell markers that are expressed in 
all types of stem cells [30]. For that reason it is crucial 
to determine specific stem cell markers for cells that 
can be used for clinical research, such are hMSCs. By 
determining the stem cells markers expression we 
would be able to estimate the quality of stem cells that 
must be associated with cell therapy efficacy. 
Therefore, we have examined changes of stem cell 
markers expression during osteodifferentiation of 
hMSCs. Here we report effects of osteodifferentiation 
on OCT-4 and SOX-2 mRNA and protein expression. 
 
 
Materials and Methods 
 
Appropriate regulatory approval from Medical 
Ethics Committee of Clinic for Traumatology Zagreb 
was taken before initiating the experiments. 
Human mesenchymal stem cells, cell lines 
and culture conditions 
The hMSCs were isolated and propagated 
using previously described methods (Romanov et al. 
2005). Two human cancer cell lines were used in the 
experiment: glioma cell line A1235 and liver cell 
cancer line HepG2. The cells were kindly provided by 
Prof. M. Matulić, University of Zagreb, The Faculty of 
Science (Croatia). Both cell lines were cultured in a 
medium which contained Dulbeccoˈs Modification of 
Eagleˈs Medium (Sigma-Aldrich) supplemented with 
10% FBS (Gibco) and penicillin (100 
U/ml)/streptomycin (100 µg/ml) (Sigma-Aldrich) at 
37°C in a humidified atmosphere containing 5% CO2. 
 
In vitro differentiation of hMSCs into 
osteogenic lineage 
Three or four passages of BMSCs were 
adjusted to a concentration of 47 500 cells/well in a 6-
well plate (Corning) in proliferation medium DMEM 
supplemented with 10% FBS, penicillin/streptomycin 
(P/S) and 10 ng/ml FGF2. The cells were cultured in a 
humidified incubator (37°C, 5% CO2) with renewal of 
the culture medium every 3 days. The cells were 
tested for their known ability to differentiate into 
osteogenic lineages by growing them in osteogenic 
induction medium when the plates were 100% 
confluent. Culture media was then replaced with 
osteogenic induction medium (αMEM 10% FBS + P/S 
+ 50 μg/ml ascorbic acid + 4 mM β-glycerophosphate 
+ 1 μM dexamethasone) after 24 hours and cells were 
maintained 14 more days under differentiating 
conditions. All the osteogenic induction factors were 
purchased from Sigma-Aldrich. Medium was replaced 
every 2 days. Process of differentiation was held for 
14 days, and day 0 was marked as the day when 
differentiation medium was added. 
 
Determination and quantification of alkaline 
phosphatase (ALP) activity 
After osteogenic differentiation, cells were 
washed in PBS, briefly fixed with citrate-acetone-
formaldehyde fixative and ALP expression was 
assessed using the ALP staining kit (86R, Sigma-
Aldrich) according to the manufacturer's instructions. 
The results were recorded using a scanner. The 
alkaline phosphatase activity was assessed 14 days 
after osteogenic induction. Cell layers were twice 
washed in PBS and the activity was measured by 
using p-nitrophenyl phosphate (Sigma-Aldrich) as a 
substrate. Briefly, cells were incubated with p-
nitrophenyl phosphate in substrate buffer (50 mM 
glycin, 1mM MgCl2, pH 10.5) at room temperature for 
10 min. Supernatant was mixed with 1 ml 1M NaOH 
and absorbance at 405 nm was recorded [32]. Each 
experiment was done in triplicates and repeated at 
least three times. 
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RNA extraction and real-time quantitative 
PCR 
Total RNA was collected from 14 days old 
osteoblast cultures as well as from undifferentiated 
hMSCs and two human cancer cell lines using TRIzol 
reagent (Invitrogen Life Technologies) according to 
manufacturer’s instructions. Briefly, cell layers were 
washed with PBS and scrapped and homogenized in 
1 ml TRIzol. RNA was treated with DNase I 
(Invitrogen) to remove genomic DNA and 3 µg of total 
RNA was reverse transcribed to cDNA using 
Superscript III First-Strand Synthesis System for RT-
PCR (Invitrogen) according to the manufacturer's 
instructions. Reverse transcription was performed in 
thermomixer (Eppendorf) at following conditions: 10 
minutes at 20°C, 1 hour at 42°C, 5 minutes at 99°C 
and 5 minutes at 5°C. Gene expression levels were 
determined by real time-qPCR using Power SYBR 
Green Mastermix (Applied Biosystems). Primers 
(Sigma-Aldrich) used to determine gene expression 
levels were presented in Table 1. The PCR reaction 
conditions were as follows: 10 minutes at 95°C for 1 
cycle, 15 seconds at 95°C and 1 minute at 60°C for 40 
cycles. Quantitative RT-PCR was performed on 7500 
Fast PCR system (Applied Biosystems). Expression 
levels were normalized to β-actin. Relative expression 
of target genes was calculated using the ΔΔCt 
method. Stem cell markers expression in 
differentiated cultures (day 14) was normalized to 1 as 
well as BSP and AP expression in 14 days old hMSCs 
cultures (day 14). 
Table 1: Primers used for quantitative real-time PCR 
 
 
Immunocytochemistry 
Cells were seeded in 35 mm Petri dishes. 
Medium was removed, cell layers were rinsed in ice 
cold PBS, fixed in 4% paraformaldehyde for 15 min 
and washed in PBS. Cells were permeabilized with 
0.25% Triton-X-100 (Packard) and blocked with 1% 
bovine serum albumin (BSA) in PBS for 30 min. Used 
primary antibodies were ab19857 rabbit polyclonal 
anti-Oct4 (Abcam) diluted 1:100, ab97959 rabbit 
polyclonal anti-Sox2 (Abcam) diluted 1:100 in 1% BSA 
and ab21624 rabbit polyclonal anti-Nanog (Abcam) 
diluted 1:100. All antibodies were applied for 1 hour at 
room temperature. Secondary antibody (Alexa Fluor® 
488 Donkey Anti-Rabbit IgG (H+L), Invitrogen) were 
applied for 1 hour at room temperature in a dark room. 
Cells were further counterstained for 1 min with 
Hoechst solution (1µg/ml) and imaged with CCD 
camera on Olympus BX51. 
 
Statistical analysis 
A statistical analysis of the data was 
performed using a one-way ANOVA analysis of 
variance followed by a Duncan test using the 
STATISTICA 12 program (StatSoft, Inc.,). Statistical 
significance was set at p < 0.05. 
 
 
Results 
 
Bone marrow-derived human mesenchymal 
stem cells were propagated in vitro and osteogenic 
differentiation was induced. The level of differentiation 
was assessed by analysis of bone markers. Early 
marker of osteoblast differentiation is the activity of 
alkaline phosphatase (AP). The AP activity was 
evaluated before and after osteogenic differentiation 
by cytochemical staining. The quantitative method 
where p-nitrophenil phosphate was used as a 
substrate, showed 6-fold increase in AP activity on 
day 14 compared to undifferentiated culture (Figure 
1A).  
 
Figure 1: High alkaline phosphatase activity is an indication of 
successful differentiation of hMSCs into osteoblast after 14 days of 
osteoinduction. The alkaline phosphatase (AP) activity was 
measured by using p-nitrophenyl phosphate as a substrate. This 
quantitative method has shown higher alkaline phosphatase activity 
in differentiated hMSC cultures (Day 14) than in undifferentiated 
cultures (Day 0) (A). This result has been confirmed by AP 
cytochemical staining (B, C). Red dye deposits indicate sites of 
alkaline phosphatase activity in hMSC cultures on day 14 and just a 
few undifferentiated hMSCs were red. The data are expressed as 
the means + SD of triplicate determination (*P<0.05). 
 
These findings are in coherence with results 
obtained from the cytochemical staining of day 0 and 
day 14 cultures (1B, 1C). Further analysis of 
differentiation included quantitative analysis of mRNA 
levels by real-time qPCR. We analyzed expression of 
two genes, alkaline phosphatase (AP) as an early 
marker of osteoblast differentiation and bone 
sialoprotein (BSP) as an intermediate to late marker of 
osteoblast differentiation with the peak of expression 
on day 14. The 5-fold increase of AP mRNA and 10-
fold increase of BSP mRNA confirmed that MSCs 
differentiated into osteoblast lineage after 14 days of 
osteogenic induction (Figure 2). 
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Figure 2: Relative mRNA expressions of osteogenic markers 
detected by real-time quantitative PCR on day 0 and day 14. The 
relative gene expression of BSP and AP was analyzed by ΔΔ cycle 
threshold method and the values were normalized to β-actin 
expression. Those values were then normalized to hMSCs after 14 
day of osteoinduction. Data are represented as an average of three 
independent patient samples and error bars represent mean value 
+ SD (*P<0.05). Abbreviations: BSP, bone sialoprotein; AP, alkaline 
phosphatase; hMSCs, human Mesenchymal Stem Cells 
 
To estimate the expression of pluripotency 
genes, we analyzed OCT-4 and SOX-2 mRNA levels 
by real-time qPCR prior and post differentiation of 
human MSCs. To confirm data on protein level, we 
performed immunostaining for OCT-4 and SOX-2. 
Data were compared with positive controls, tumor cell 
lines positive for OCT4/SOX2 expression, glioma cell 
line A1235 and liver cell cancer line HepG2. 
 
Figure 3: Expression levels of OCT-4 and SOX-2 genes in hMSCs 
after 14 days of osteoinduction, undifferentiated hMSCs and two 
human cancer cell lines A1235 and HepG2 detected by real-time 
qPCR. OCT-4 is expressed in undifferentiated hMSC (Day 0) but 
expression of OC-T4 gene does not go down after osteoinduction 
on day 14. Relative mRNA expression of OCT-4 in Hep G2 cell line 
was 9.9 x more expressed than in undifferentiated hMSCs (A). 
Transcription factor SOX-2 is expressed in undifferentiated hMSCs 
and its expression goes down after osteoinduction on day 14. 
Relative mRNA expression of SOX-2 in Hep G2 cell line was 5321.9 
x more expressed than in undifferentiated hMSCs while in 
glioblastoma A1235 cell line was 3169.8 x respectively (B). The 
quantity of gene expression was normalized to β-actin to determine 
the quantitative differences. Data are represented as an average of 
three independent patient samples and error bars represent mean 
value + SD. In the columns marked with asterisk * the mean values 
are significantly different then control (Hep G2) (A) or A1235 and 
Hep G2 (B), respectively, according to Duncan test (*P<0.05) 
Expression of OCT-4 mRNA was detected 
prior the differentiation and it unexpectedly increased 
2-fold after differentiation. However, the levels of 
expression are very low when compared to OCT-4 
positive tumor cell line HepG2 (Figure 3A). To confirm 
our findings on protein level we performed 
immunostaining and protein OCT-4 was detected in 
cultures before and after differentiation (Figure 4A). 
OCT-4 signal was localized in the cell nuclei as 
expected for transcription factor (Figure 5). 
 
Figure 4: Immunostaining for OCT-4 did not show any changes in 
OCT-4 protein level in osteo-differentiated hMSC cultures compared 
to undifferentiated. Osteoblast and undifferentiated hMSCs were 
both positive for OCT-4 expression and had a nuclear localization of 
OCT-4 (A). Immunofluorescence staining for SOX-2 did not confirm 
levels of SOX-2 protein in osteo-differentiated hMSCs (Day 14) nor 
in undifferentiated hMSCs (Day 0) (B). Liver cell cancer line HepG2 
has been used as positive control for OCT-4 expression. 
Glioblastoma A1235 cell line has been used as positive control for 
SOX-2 expression and for no primary antibody control (-ctrl) as well. 
Nuclei were stained with Hoechst (200x, CCD camera on Olympus 
BX51). Abbreviations: ICC, immunocytochemistry; BF, bright field; 
d0, the day when differentiation medium was added; d14, 14th day 
of osteogenic differentiation 
 
Expression of SOX-2 mRNA was also 
detected in undifferentiated MSCs and after 
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differentiation at day 14 was downregulated. Overall 
expression of SOX-2 was extremely low when 
compared to positive control cell lines A1235 and 
HepG2. At protein level, SOX-2 was undetectable 
before and after differentiation. Therefore, findings at 
protein level did not reflect findings on mRNA level. 
 
Figure 5: Fluorescence microscopy image of undifferentiated 
hMSCs immunostained for OCT-4. Immunofluorescence staining for 
Hoechst (blue) and OCT-4 (green) indicates a nuclear localization 
of OCT-4 protein (20x, CCD camera on Olympus BX51) 
 
 
Discussion 
Human mesenchymal stem cells (hMSCs) 
provide an excellent source of multipotent progenitor 
cells that are present in bone marrow as well as in 
most of connective tissues. Due to their proliferation 
and differentiation capacity, they are able to 
differentiate toward multiple mesodermal lineages 
[13]. In this work, we have examined hMSCs 
osteogenic potential. Human MSCs were 
differentiated into osteoblasts by standardized method 
where hMSCs are treated with osteogenic inductors, 
ascorbic acid, β-glycerophosphate and 
dexamethasone [33]. Here, we have investigated and 
compared the change of osteogenic markers 
expression and the alteration of stem cell markers 
expression OCT-4 and SOX-2 during osteogenic 
differentiation of hMSCs. 
We have followed the change of early and 
late osteogenic markers. Alkaline phosphatase was 
used as an early osteogenic marker and bone 
sialoprotein as late marker. Our results showed that 
on day 14 all observed osteogenic markers are highly 
expressed and hMSCs were differentiating towards 
osteoblast lineage. As previously described [34] we 
have also observed a few distinct alkaline 
phosphatase positive cells on day 0. In this report, we 
have investigated weather two stem cell markers, 
OCT-4 and SOX-2, known to regulate potency and 
self-renewal of embryonic stem cells, were expressed 
in hMSCs and how their expression changed after 
osteoinduction. OCT-4 and SOX-2 mRNA expression 
was examined at mRNA level by qPCR and at protein 
level by immunocytochemistry. Real-time qPCR 
revealed that OCT-4 and SOX-2 mRNAs are 
expressed in hMSCs and their expression is very low 
when compared with tumor cell lines used as a 
positive control. After differentiation the level of OCT-4 
increased and the level of SOX-2 decreased. 
Immunocytochemical staining revealed that OCT4 
protein is expressed in all hMSCs and stays 
expressed on day 14, localized in the nuclei. In 
contrast to previous observations [11], SOX2 have not 
been detected neither in hMSCs on day 0 nor in 
osteoblasts on day 14. 
We demonstrate presence of stem cell 
markers OCT-4 and SOX-2 in human mesenchymal 
stem cells at mRNA level. Immunocytochemical 
analysis revealed OCT4 expression in nuclei but not 
in cytoplasm as previously has been demonstrated 
[34). In past decade, many controversial results have 
been obtained regarding the expression and the role 
of stem cell transcriptional factors in adult stem cells. 
OCT-4 and SOX-2 were undoubtedly confirmed in 
some types of adult progenitor and multipotent stem 
cells [34–37]. They are expressed in tumor cells [38–
40] and might be responsible for cancer stem cells 
resistance to chemotherapy [41]. Previous reports 
showed inconsistent results in the expression of stem 
cell markers in adult stem cells. Beltrami et al., as well 
as some other groups have confirmed OCT-4 and 
SOX-2 and NANOG stem cell markers expression in 
mesenchymal stem cells [11, 13, 34] but Pierantozzi 
et al. have not detected OCT-4 and NANOG in adult 
hMSCs [24]. Little is known about the role of OCT-4 
and SOX-2 in adult stem cells. OCT-4 gene 
knockdown promotes differentiation thereby that 
transcriptional factor play an important role in stem 
cell self-renewal [42]. We find that hMSCs express 
low levels of OCT-4, what is crucial for multipotency 
and self-renewal of these adult stem cells. It has been 
previously reported that increased expression of OCT-
4 causes increased differentiation efficiency towards 
osteoblasts [43]. 
Immunohistochemical staining did not confirm 
OCT4 protein in vivo, in bone marrow sections. There 
is a possibility that ex vivo expansion of human 
mesenchymal stem cells causes activation of 
endogenous OCT-4 gene expression. Therefore, 
OCT-4 might play an important role for maintaining 
potency in somatic stem cells [28] including hMSC. 
Synthesis and degradation of OCT-4 protein is very 
rapid process and alteration of OCT-4 transactivation 
potential in response to extracellular signals is 
reversible [44]. This kinetic is not completely 
understood yet, but might explain why very high OCT-
4 expression is present in osteoblasts on day 14. 
Relative amounts of OCT-4 protein are essential for 
proper differentiation and early development of an 
organism because it determines developmental 
directions. Post-translational modification of OCT-4 by 
sumoylation can enhance OCT-4 stability, DNA 
binding and transactivation [45]. OCT-4 is 
ubiquitinated by Wwp2 and degradated during 
differentiation of embryonal carcinoma cell line but 
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does not affect OCT-4 protein level in embryonic stem 
cells [46]. These post-translational modifications are 
important for OCT-4 stability, activity and degradation, 
so these mechanisms may maintain its quantity during 
differentiation of hMSCs. 
SOX2 is a transcription factor co-expressed 
with OCT-4. It has been identified a crucial player in 
the maintenance and differentiation of adult stem cells 
such as in neural stem cells. Seo et al. showed that 
SOX-2 maintains self-renewal and proliferation of the 
osteoblast precursors [47]. SOX-2 inactivation in 
cultured primary osteoblasts has been shown to 
cause exhaustion of their proliferative ability and 
senescence [48]. Our findings support the existence 
of progenitors that express SOX-2 among the 
population of hMSCs, however the levels detected by 
qPCR may be under the detection limit of 
immunocytochemistry or posttransciptional regulation 
may be responsible for absence of protein. 
Downregulation of SOX-2 after the differentiation is 
consistent with suggested role of SOX-2. 
Despite the fact that probably there is no 
universal stem-cell marker which could be applied to 
all types of stem cells [30], it is important to define 
stem cell markers specific for clinically relevant cell 
types such as MSCs. These markers could be used 
for the evaluation of stem cell differentiation potential. 
In this study, since hMSCs have well defined 
osteogenic markers, we have tried to define some 
stem cell markers in these cells. We have evaluated 
two potential candidates, OCT-4 and SOX-2. It is 
crucial to further examine their function in hMSCs as 
well as in osteoblasts. It is important to be able to 
evaluate the quality of stem cells, because the stem 
cell potential is certainly associated with the potential 
results of cell therapy. 
One of the biggest problems in cell therapy is 
a potential malignant transformation of stem cells. It is 
well known that the stem and tumor cells in some 
aspects of their biology are very similar. During the 
process of the tumor stem cell dedifferentiation, re-
expression of some stem cell markers occurs [40] and 
very often OCT-4 levels are dramatically increased in 
cancer cells [49]. Potentially, by monitoring the 
expression of OCT-4 gene in stem cells we could 
predict the behavior of cells in terms of malignant 
transformation. This is another reason why it is 
necessary to investigate the role of pluripotency 
genes in somatic stem cells. 
In conclusion, bone marrow-derived 
mesenchymal stem cells that are expanded in culture 
in the presence of FGF2 clearly express low levels 
pluripotency markers OCT-4 and SOX-2 mRNA. 
Protein OCT-4 is detected in cell nuclei before and 
after differentiation while SOX-2 is not detected. 
Expression of OCT-4 is not desirable property of cells 
that are going to be applied in the clinical setting. We 
conclude that culture conditions do have an effect on 
stem cell marker expression and it is important to 
standardize cultivation conditions in order to better 
predict cell behavior. It is necessary to clarify better 
the role and mechanism of action of core pluripotency 
genes in mesenchymal stem cells following their 
cultivation in vitro. 
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